Medical device company RadiaDyne reported on Thursday the milestone commercial sale of its diagnostic patient dose monitoring platform, the OARtrac system.

The company sold the OARtrac system to the cancer treatment facility, University Hospital's Cleveland Medical Center (UH), located in Cleveland, Ohio.

UH was reportedly the first hospital to utilise the OARtrac technology to monitor rectal dose during a SBRT prostate treatment and skin dose during a gynecologic radiotherapy treatment.

According to the company, OARtrac is the first of its kind patient dose monitoring platform which provides gold standard accuracy, real-time pinpoint measurement and proprietary intracavitary delivery devices to measure physical dose during radiation treatment. It provides critical dose feedback, which helps facilitate adaptive radiotherapy with the goal to reduce side effects and offer better clinical outcomes.